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The calculation of utilization increases reflects the change
in the aggregate number of prescriptions filled. The cal-
culation of annual increase in expenditures reflects the
change in expenditure from an old set of drugs to a new
set. To estimate the impact of pipeline drugs, case scenar-
ios were performed around HCFA’s baseline projections
for future drug trends. The compounded, annual, growth-
rate decrease of new drug approvals was used as a lower
bound, while a constant increase in the pipeline projection
provided the upper bound.
RESULTS: Historically, slightly less than one-third of the
increase in drug expenditure was due to price increases
on existing drugs, approximately one-third was due to in-
creases in the utilization of existing drugs, and slightly
more than one-third was due to product shift. Based on
our data, the historical increase in expenditures was 15%
for all drugs, 25% for newer drugs and 7% for older
drugs. Our lower and upper bound scenarios projected
national drug expenditures of $191.56 billion and
$215.62 billion, respectively, for 2004.
CONCLUSION: The impact of pipeline drugs on future
drug trends is significant. There is considerable variation
surrounding the impact of pipeline drugs on future drug
expenditures based on several plausible scenarios.
CANCER II
CN4
THE IMPACT OF THE DIAGNOSIS OF CANCER 
ON OUT-OF-POCKET HEALTH-CARE 
EXPENDITURES MADE BY THE US ELDERLY
Langa K1, Hayman J1, Chernew M1, Kabeto M1, Slavin M2, 
Fendrick AM1
1University of Michigan, Ann Arbor, MI, USA; 2Ortho Biotech, 
Raritan, NJ, USA
If the “total” costs of a disease, such as cancer, are to be
accurately quantified, out-of-pocket expenditures (OOPE)
made by patients and caregivers must be added to costs
incurred by third party payers (direct medical) and em-
ployers (lost productivity). Prior studies of OOPE by the
elderly used small geographically restricted samples and
narrow patient subgroups.
OBJECTIVES: To rigorously quantify OOPE for individ-
uals older than 70 years in the United States. To empha-
size cancer-related OOPE, three patient cohorts were ex-
amined: 1) no cancer (No CA); 2) history of cancer but
not undergoing treatment (CA/No Tx), and 3) undergo-
ing active cancer treatment (CA/Tx).
METHODS: Data from the Asset and Health Dynamics
Study, a nationally representative, longitudinal survey of
community-dwelling elderly were used. Respondents de-
noted cancer status and reported OOPE over two years
for: 1) nursing home/hospitals; 2) doctor visits; 3) pre-
scription drugs, and 4) “special” services. Using a multi-
variable two-part regression model to control for differ-
ences in co-morbidity, health status, living situation, and
sociodemographics, the additional cancer-related OOPE
was estimated.
RESULTS: Of the 6576 respondents, 5553 (84%) re-
ported No CA, 843 (13%) reported CA/No Tx, and 180
(3%) reported CA/Tx. Cancer diagnosis and current can-
cer treatment were significant predictors of increased
OOPE compared to no cancer. The mean annual OOPE
for No CA, CA/No Tx, and CA/Tx groups was US$1900,
US$2400, and US$3300, respectively (p  .001). Hospi-
tals (US$1400/yr) and prescription drugs (US$1100/yr)
were the largest OOPE components for the CA/Tx group.
The incremental OOPE for CA/No Tx and CA/Tx pa-
tients approximates US$1.5 billion annually.
CONCLUSIONS: OOPE for elderly individuals with a
history of cancer or ongoing therapy are substantial and
significantly greater than for those without cancer. If
OOPE remain unaccounted for, total costs of cancer will
be consistently underestimated. Economic evaluations of
interventions aimed at cancer prevention and treatment
must account for OOPE.
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OBJECTIVE: The aim of this study was to validate a self-
completed questionnaire in Upper Limb Lymphoedema.
METHODS: A qualitative survey was conducted to iden-
tify patients’ complaints. This questionnaire was admin-
istered to 154 patients. Principal component analysis was
used to identify dimensions. A validation study was con-
ducted in 304 patients. Six instruments have been used in
the case report form: volume differences between the
healthy and the affected arms; composite symptom scales
completed by clinicians from patient interviews; ULL-27
and SF-36 scales completed by patients; overall opinion
of doctors and patients. Internal validity was checked
through factorial analysis. Trait validity was investigated
by correlating the domains rated with ULL-27 with the
SF-36 scale. Nomologic validity was tested by comparing
the means of the ULL-27 subscales across severity stages.
Sensitivity was tested only in patients with progressive
disease between D0 and D28 by comparing mean sub-scores
for the ULL-27 scale and by calculating the effect size.
RESULTS: Three hundred four patients were included in
the study. Factorial analysis isolated three dimensions:
physical (15 items), psychological (7 items), and social
withdrawal (5 items). The Cronbach coefficients are
greater than 0.80 for all dimensions. The Spearman cor-
relations clearly distinguish the different life domains
from each other. At D0 the physical and social dimen-
sions of ULL-27 scale were significantly correlated with
severity of illness but it was not the case for the psycho-
